Research Article

Growth Hormone (GH) Enhances Endogenous Mechanisms of Neuroprotection and Neuroplasticity after Oxygen and Glucose Deprivation Injury (OGD) and Reoxygenation (OGD/R) in Chicken Hippocampal Cell Cultures

Juan David Olivares-Hernández, Jerusa Elienai Balderas-Márquez, Martha Carranza, Maricela Luna, Carlos G. Martínez-Moreno, and Carlos Arámburo

Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Qro., 76230, Mexico

Correspondence should be addressed to Carlos Arámburo; aramburo@unam.mx

Received 25 March 2021; Accepted 14 August 2021; Published 16 September 2021

As a classical growth promoter and metabolic regulator, growth hormone (GH) is involved in development of the central nervous system (CNS). This hormone might also act as a neurotrophin, since GH is able to induce neuroprotection, neurite growth, and synaptogenesis during the repair process that occurs in response to neural injury. After an ischemic insult, the neural tissue activates endogenous neuroprotective mechanisms regulated by local neurotrophins that promote tissue recovery. In this work, we investigated the neuroprotective effects of GH in cultured hippocampal neurons exposed to hypoxia-ischemia injury and further reoxygenation. Hippocampal cell cultures obtained from chick embryos were incubated under oxygen-glucose deprivation (OGD, <5% O₂, 1 g/L glucose) conditions for 24 h and simultaneously treated with GH. Then, cells were either collected for analysis or submitted to reoxygenation and normal glucose incubation conditions (OGD/R) for another 24 h, in the presence of GH. Results showed that OGD injury significantly reduced cell survival, the number of cells, dendritic length, and number of neurites, whereas OGD/R stage restored most of those adverse effects. Also, OGD/R increased the mRNA expression of several synaptogenic markers (i.e., NRXN1, NRXN3, NLG1, and GAP43), as well as the growth hormone receptor (GHR). The expression of BDNF, IGF-1, and BMP4 mRNAs was augmented in response to OGD injury, and exposure to OGD/R returned it to normoxic control levels, while the expression of NT-3 increased in both conditions. The addition of GH (10 nM) to hippocampal cultures during OGD reduced apoptosis and induced a significant increase in cell survival, number of cells, and doublecortin immunoreactivity (DCX-IR), above that observed in the OGD/R stage. GH treatment also protected dendrites and neurites during OGD, inducing plastic changes reflected in an increase and complexity of their outgrowths during OGD/R. Furthermore, GH increased the expression of NRXN1, NRXN3, NLG1, and GAP43 after OGD injury. GH also increased the BDNF expression after OGD, but reduced it after OGD/R. Conversely, BMP4 was upregulated by GH after OGD/R. Overall, these results indicate that GH protective actions in the neural tissue may be explained by a synergic combination between its own effect and that of other local neurotrophins regulated by autocrine/paracrine mechanisms, which together accelerate the recovery of tissue damaged by hypoxia-ischemia.

1. Introduction

Ischemic stroke is a serious cerebrovascular event caused by a blockage of blood supply and oxygen to the brain, leading to damage or death of brain cells, which produces a severe neurological impairment, or even decrease [1]. It is well established that cerebral ischemia induces a pathophysiological response in the neural tissue that leads to apoptotic and
necrotic cell death [2], neural structural damage, and synaptic loss, which then contribute to the drastic deficiency of neurological functions [3].

In addition to its classical actions on growth and metabolism, growth hormone (GH) has been reported to play a relevant role, as a neurotrophic factor, on brain repair after traumatic brain injury (TBI) and stroke [4–6]. The neurotrophic actions of GH in the central nervous system (CNS) include prosurvival effects during embryonic development [7, 8], neurogenesis in the adult brain [9], structural plasticity [10, 11], and synaptogenesis [12], among others. These effects could be associated with the cognitive and motor improvement observed in TBI patients, with or without growth hormone deficiency (GHD), who received GH therapy [6, 13–15].

It has been reported that after neural injury, there is an activation of local mechanisms that induce neuroprotection and neuroplasticity which, in some cases, also promote proliferation of newly born neurons and migration of neural precursor cells into the lesioned peri-infarct region [16, 17]. The cellular and molecular mechanisms behind the brain capacity to repair an infarcted region are still largely undetermined; although, the expression and release of endogenous neurotrophic factors have been shown to be significantly increased during ischemic events [18–21]. Interestingly, GH is also synthesized by cells surrounding the peri-infarcted area suggesting that local autocrine/paracrine mechanisms are triggered after a neural injury [22]. Moreover, it has been shown that the expression of growth hormone receptor (GHR) is increased in the injured tissue, facilitating the neuroprotective action of this hormone [23].

Neuroprotective actions of GH treatments on either brain ischemia in vivo or oxygen-glucose deprivation (OGD) injury in vitro have been previously documented [24–26]. In the hippocampus, GH significantly reduced apoptotic cell death rate after an experimental stroke [25], decreased loss of neural tissue, and increased the expression of neurotrophic factors, synaptogenesis, and myelination biomarkers, as well as the formation of new blood vessels within the peri-infarct area, and provoked an improvement in cognitive function in experimentally stroked mice [26]. Recent studies showed that the administration of GH after experimental stroke promoted neurogenesis and stimulated synaptic plasticity and angiogenesis within the peri-infarct region, which were associated with an improvement in the motor function [27]. Furthermore, GH treatment promoted remote hippocampal plasticity and enhanced cognitive recovery after cortical injury [28]. Relevantly, GH addition also increased the expression of neurotrophic factors, such as BDNF and IGF-1, which in turn could participate in the endogenous neuroprotective response that occurs after ischemic injury [4, 25, 29].

Given the increasing number of reports regarding the beneficial effects of GH treatment in patients with brain injury and stroke [4, 5, 14, 30–32], as well as its therapeutic potential to treat neurodegenerative diseases [33, 34], it is pertinent to further investigate the interactions between the administration of GH and the expression of endogenous neurotrophic factors that may be involved in local neuroprotection mechanisms. Thus, the aim of the present study was to evaluate the neuroprotective role of GH in cultured hippocampal neurons that were injured by exposition to OGD and then submitted to an additional reoxygenation (OGD/R) period.

This work shows that OGD injury (24 h) significantly affects cell survival, reduces neurite outgrowth, and alters the expression of several synaptogenic markers, such as neurexins (NRXN1, NRXN3), neuroligins (NLG1), and growth associated protein 43 (GAP43), in hippocampal neurons. Interestingly, exposure of the harmed cultures to reoxygenation and normal glucose incubation conditions (OGD/R), for another 24 h, reverses most of the adverse effects of OGD. Additionally, it is shown that the expression of several neurotrophic factors (i.e., BDNF, NT-3, IGF-1, and BMP4) is significantly increased after OGD, whereas the GHR expression was upregulated only in the OGD/R condition. Furthermore, it was found that administration of GH treatments, both under OGD and OGD/R conditions, clearly stimulated significant plastic changes by promoting cell survival, enabling an increase of neurite outgrowth, and inducing a rise of synapse formation markers, in levels above those observed in the OGD/R condition. These protective neurotrophic actions of GH are probably mediated through a synergistic mechanism between GH and other endogenous neurotrophins.

2. Materials and Methods

2.1. Animals. Fertilized eggs (Gallus gallus, White Leghorn) were obtained from Pilgrim’s Pride (Querétaro, México) and were incubated at 39°C in a humidified air chamber (IAMEX, México) until embryonic day 15 (ED15). The eggs were rotated one quarter of a revolution every 50 min during incubation. All experimental procedures were conducted according to national (NOM-062-ZOO-1999) and international (The guide for care and use of laboratory animals, U.S. National Research Council) guidelines and were approved by the bioethical committee of the Instituto de Neurobiología, UNAM.

2.2. Embryonic Chicken Hippocampal Cell Cultures. Chick embryos (ED15) were anesthetized in ovo by cooling them on ice for 5 min and then euthanized by decapitation. The brain was pulled out quickly from the skull, and it was coronally chopped into a block, at the level of hippocampus using a microsurgical blade. The slices were examined under the stereoscopic microscope, and the hippocampi were microdissected, using the lateral ventricles as reference. The hippocampal tissues from 15 embryos were digested in 0.002% trypsin-EDTA (Sigma-Aldrich, St. Louis, MO, USA) solution at 39°C for 10 min. Trypsin digestion was stopped by the addition of an equal volume of neurobasal medium supplemented with 2% B27, Gluta-MAX, and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA). The digested tissue was centrifuged at 1800 g for 5 min, and the pellet was resuspended in the same medium. The tissue was mechanically triturated with a glass pipette and passed through a 40 μm pore filter.
Cells were counted in a Neubauer chamber using the trypan blue exclusion method, and then \((1 \times 10^5)\) plated in 12-well plates (Costar Corning, NY, USA) coated with 50 \(\mu g/mL\) poly-L-lysine, and incubated in neurobasal-B27 (Nb-B27) media. The cell cultures were stabilized in a humidified incubator at 39°C, under an atmosphere of 95% air/5% CO\(_2\), for 5 days.

2.3. Treatments. In an in vitro model of cerebral ischemia/reperfusion was established by incubating hippocampal cell cultures first under oxygen-glucose deprivation (OGD) and then under reoxygenation (OGD/R). OGD was induced by replacing Nb-B27 medium for DMEM-Low glucose 1× (1g/L, Gibco, Grand Island, NY, USA) medium; then, the hippocampal cell cultures were incubated in a humidified hypoxic chamber (Napco E Series, Model 302 CO\(_2\) incubator), for 24 h at 37°C, and flushed with a 95% N\(_2\)/5% CO\(_2\) gas mixture. The resulting oxygen concentration within the chamber (<5% O\(_2\)) was monitored with an ambient oxygen sensor (BW Technologies, Arlington, TX, USA) and maintained throughout the experiment. Immediately after this treatment, a group of cells were used as hypoxia-ischemia controls (ODG group) and analyzed, whereas others were exposed to reoxygenation for another 24 h (OGD/R group).

The OGD/R condition was achieved by substituting DMEM-Low glucose medium for Nb-B27 medium and incubating the cultures for additional 24 h under normoxic conditions (95% air/5% CO\(_2\)). After the OGD/R stage, the hippocampal cell cultures were maintained in normal Nb-B27 medium under normoxic conditions (normoxia group).

Recombinant chicken growth hormone (rcGH, Revholt, PRL, Israel) was administered to the cell cultures in DMEM-Low glucose medium or Nb-B27 medium at several concentrations (1, 10, 100 nM). The treatments were added during OGD (OGD + GH group) and maintained during OGD/R (OGD/R + GH group). Likewise, cultures under normoxic conditions were also treated with GH (normoxia + GH group). As negative controls, each of the groups was incubated without GH.

2.4. Determination of Cell Survival. The effects of treatments upon cell survival were assessed by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, using a Vybrant kit (Molecular Probes, Eugene, OR, USA). Briefly, cells (1 × 10\(^5\)) were cultured in 96-well plates (Costar Corning, NY, USA) and stabilized for 5 days at 39°C in a humidified chamber with an atmosphere of 95% air/5% CO\(_2\). After the treatments, the cell cultures were fixed with 4% paraformaldehyde in tris-buffered saline (TBS), pH 7.4, for 20 min, and then washed with TTBS (TBS + 0.05% Tween 20), 3 × 10 min. To block nonspecific staining, the cells were incubated with 5% nonfat milk (Bio-Rad, Hercules, CA, USA) in TBS for 2 h at room temperature (RT) and then washed in TTBS (3 × 10 min). Primary antibodies (Table 1) were diluted (1:250) in 1% nonfat milk TTBS solution, added to the fixed cells, and then incubated overnight at RT. The next day, cells were washed in TTBS (3 × 10 min) and further incubated with the corresponding secondary antibodies (Table 1), for 2 h at RT, and then washed in TTBS (3 × 10 min). Later, the cells were incubated and counterstained with a 300 nM 4′-diamidino-2-phenylindole solution (DAPI, Invitrogen) in TBS for 10 min and washed (3 × 10 min). The plates were analyzed using an Olympus BX51 fluorescence microscope, employing a ×20 objective. The total number of DAPI positive cells (DAPI+) was estimated in at least 20 fields, in two different dishes per experiment, with a total of three independent experiments. Image analysis was performed using FIJI-ImageJ software (https://fiji.sc).

2.5. Immunocytochemistry. For immunocytochemical analysis, the cells (1 × 10\(^5\)) were grown in 35 mm FluoroDish tissue culture dishes (World Precision Instruments Inc., Sarasota, FL, USA) following the methodology previously described. After the treatments, cell cultures were fixed with 4% paraformaldehyde in tris-buffered saline (TBS), pH 7.4, for 20 min, and then washed with TTBS (TBS + 0.05% Tween 20), 3 × 10 min. To block nonspecific staining, the cells were incubated with 5% nonfat milk (Bio-Rad, Hercules, CA, USA) in TBS for 2 h at room temperature (RT) and then washed in TTBS (3 × 10 min). Primary antibodies (Table 1) were diluted (1:250) in 1% nonfat milk TTBS solution, added to the fixed cells, and then incubated overnight at RT. The next day, cells were washed in TTBS (3 × 10 min) and further incubated with the corresponding secondary antibodies (Table 1), for 2 h at RT, and then washed in TTBS (3 × 10 min). Later, the cells were incubated and counterstained with a 300 nM 4′-diamidino-2-phenylindole solution (DAPI, Invitrogen) in TBS for 10 min and washed (3 × 10 min). The plates were analyzed using an Olympus BX51 fluorescence microscope, employing a ×20 objective. The total number of DAPI positive cells (DAPI+) was estimated in at least 20 fields, in two different dishes per experiment, with a total of three independent experiments. Image analysis was performed using FIJI-ImageJ software (https://fiji.sc).

2.6. SDS-PAGE and Western Blot Analysis. Hippocampal cell cultures (4 wells per experimental group) were homogenized with an ultrasonicator (GE 130PB, Cole-Parmer, Vernon Hills, IL, USA) in 0.05 M HCl-Tris, pH 9.0 buffer, in the presence of a protease inhibitor cocktail (Mini-complete, Roche, Mannheim, Germany). The extracts were centrifuged (12,500 rpm, 15 min), and the supernatants were collected. Total proteins were determined by the Bradford assay with a Bio-Rad assay (Bio-Rad, Hercules, CA, USA), and 50 \(\mu g\) of protein/lane was separated in 12.5% SDS-PAGE slabs and then transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) as previously described [24]. For immunoblotting, membranes were blocked with 5% nonfat milk (Bio-Rad) in TBS for 2 h. Then, membranes were incubated overnight at RT with the corresponding primary antibodies (Table 1) in TBS. After washing the membranes with TTBS (3 × 10 min), they were incubated for 2 h with the corresponding HRP-conjugated secondary antibodies. Immunoreactive bands were visualized using the ECL blotting detection reagent (Amersham-Pharmacia, Buckinghamshire, UK) on autoradiography film (Fujifilm, Tokyo, Japan). Kaleidoscope molecular weight markers (Bio-Rad) were used as reference for molecular mass determination.

2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR). Total RNA was extracted from cells in each well (4 wells per experimental condition) by adding 100 \(\mu L\) of TRIzol (Invitrogen, Waltham, MA, USA) according to the manufacturer’s indications. RNA was purified from cellular lysates using the Zymo Direct-zol purification kit (Zymo Research Corp., Irvine, CA, USA). Genomic DNA contamination was removed by DNase I treatment (Invitrogen,
Waltham, MA, USA) for 15 min at RT. The cDNA was synthesized from 2 μg of total RNA using 100 U of M-MLV reverse transcriptase (Promega, Madison, WI, USA), 1 mM dNTPs, 0.5 μM random hexamers, for 60 min at 42 °C, in a final volume of 40 μL.

### 2.8. Quantitative PCR (qPCR).

The expression of target genes (Table 2) was quantified by qPCR using an ABI-PRISM 7900HT system (Applied Biosystems, Foster, CA, USA), using SYBR green (Maxima, Thermo Scientific, Waltham, MA, USA) in 10 μL final volume containing 3 μL of diluted cDNA and 0.5 μL of each specific primer (0.5 μM). Primer sets used (Table 2) were designed to amplify avian mRNAs and to cross intron-exon boundaries to control for genomic DNA contamination. Reactions were performed under the following conditions: initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 30 sec, and 72°C for 30 sec. Dissociation curves were included after each qPCR experiment to ensure primer specificity. The relative abundance of the corresponding mRNAs was calculated using the comparative threshold cycle (Ct) method, employing the formula 2^{-ΔΔCt} [35–37]. Gene expression determinations were performed in duplicate, from 3-4 independent experiments.

### 2.9. Determination of Apoptosis by Caspase-3 Activity.

Apoptotic cell death in cell cultures was analyzed by using a caspase-3 colorimetric assay kit (Assay Designs Inc., Ann Arbor, MI, USA). The samples (8 μg protein) of cell lysates from each treatment, standards, and blank controls were placed in 96-well microplates, by duplicate. After a 3 h incubation at 37°C, the reaction was stopped with 1 N HCl, and absorbance at 405 nm was read immediately in a 3350-UV microplate reader (Bio-Rad, Hercules, CA, USA). The caspase-3 activity was calculated as units per microgram of protein [38], normalized and expressed as percent activity relative to the OGD condition (which was considered as 100%).

### 2.10. Neurite Growth Analysis.

After the treatments, cells were stained with the neuronal biomarker β-III-tubulin and visualized using an Olympus BX51 fluorescence microscope with a ×40 objective. Images of individual neurons were captured with Lumenera software (Ottawa, CA). Neurites of each neuron (including all of its ramifications) were traced using the Simple Neuro Tracer (Fiji freeware [39]), and total dendritic length and branch order analysis were automatically measured. For each group, 20 neurons from 8-10 randomly selected fields were analyzed, from three independent experiments.

### 2.11. Statistical Analysis.

In all experiments, values were expressed as mean ± SEM. Significant differences between groups or treatments were determined by either one-way ANOVA or two-way ANOVA and Tukey’s posthoc test. Unpaired Student’s t-test was used to compare between two groups where appropriate. Values of p < 0.05 were considered to be statistically significant.

### 3. Results

#### 3.1. Characterization of Hippocampal Primary Cell Cultures and Effect of OGD Injury upon Cell Survival.

The typical morphology of the cultured embryonic chicken hippocampal neurons used in this study is shown in Figure 1, under normoxic conditions (Nx). After three days in culture, round cell bodies with short neurites were observed in the phase contrast microscope (Figure 1(a)i). At day 5, an increase in neurite length and arborization was clearly noticeable (Figure 1(a)ii). Over 80% of total cultured cells at this stage were neurons expressing β-III-tubulin (Figure 1(a)iii) and DCX (Figure S1) immunoreactivities (IR). In addition, other cellular types, such as GFAP-IR cells, were also observed in the cultures, although in a lower proportion (Figure S1).

To characterize the effect of hypoxia-ischemia upon cell viability, hippocampal neuron cultures were exposed to OGD incubation conditions for 1, 6, 12, or 24 h. As shown in Figure 1(b), there was a progressive, time-dependent, detrimental effect on the viability of neurons, which was significantly reduced at 12 h and 24 h (down to 71.52 ± 5.11% and 64 ± 5.5%, respectively), in comparison to the normoxic conditions (100% at the beginning and 98.2 ± 3.75% after 24 h of incubation). Since the neuronal injury was more evident after exposure to OGD for 24 h (Figure 1(c)), this was the time frame used in the rest of the experiments in the study.

#### 3.2. Effects of Reoxygenation (OGD/R) on OGD Injured Neurons.

In order to mimic the reperfusion phase after...
hypoxia-ischemia in our in vitro injury model, hippocampal cell cultures were first exposed to OGD for 24 h, as mentioned above, and then incubated under OGD/R conditions for another period of 24 h (Figure 2(a)). The neurons were immunostained with antibodies against DCX and β-III-tubulin, and cell nuclei were stained with DAPI with DAPI+ cell cultures exposed to OGD injury showed a strong reduction (100 ± 3 μm, p < 0.001) in relation to the injured group, although did not reach those in the Nx group. Thus, the number of neurites was significantly decreased in the OGD/R group to around one half (7.84 ± 0.45, p < 0.05, Figures 3(a)ii, 3(a)iii, and 3(b)), whereas the average length of the longest neurites was markedly reduced, up to 60% (300.5 ± 17.95 μm vs. 121 ± 5.2 μm, respectively; p < 0.0001, Figures 3(a)ii, 3(a)iii, and 3(c)). Interestingly, reoxygenation of the hippocampal cultures induced a partial recovery of these parameters, in comparison to the OGD group, although did not reach those in the Nx group. Thus, the number of neurites was significantly increased (11.22 ± 0.8, p < 0.001, Figures 3(a)ii, 3(a)iii, and 3(b)), and the average length was also augmented (240.9 ± 11.43 μm, p < 0.0001, Figures 3(a)ii, 3(a)iii, and 3(c)) in the OGD/R group.

The expression of several specific pre and postsynaptic markers in response to the different treatments was also studied by qPCR. It was found that the expression of NRXN1 and NRXN3 mRNAs was significantly increased (1.7-fold, p < 0.001, Figure 3(d); 1.3-fold, p < 0.05, Figure 3(e); respectively) under OGD conditions in comparison to the Nx group, but the NRXN3 expression returned to similar control levels after the OGD/R stage. On the other hand, the expression of NRXN3, NLG1, and GAP43 mRNAs was no different from the normoxic controls when the

| Target       | Primer | Sequence (5'-3')          | Size     | Accession number |
|--------------|--------|---------------------------|----------|-----------------|
| cBDNF        | Fwd    | AGCAGCTCAAGTGCCCTTGGAG    | 167 bp   | NM_001031616    |
|              | Rev    | TCCGCTGCTGGTACCACCTCG     |          |                 |
| cIGF1        | Fwd    | TTACCTGGGCTGGTATTTCTG     | 170 bp   | NM_001004384    |
|              | Rev    | CACCTTTGGGTTAAGGTTCT      |          |                 |
| cNT3         | Fwd    | ACGCAAGACAGACGTACACAC     | 248 bp   | NM_001109762    |
|              | Rev    | ACCACGTTCCTGGTGTTCT       |          |                 |
| cBMI4        | Fwd    | CGCTGGAGAGCTTGTATGT       | 153 bp   | NM_205237.3     |
|              | Rev    | CCCCTGAGTAAGATCGGC        |          |                 |
| cGHR         | Fwd    | ACTTACACATGGACAATGCTTA    | 180 bp   | NM_001001293.1  |
|              | Rev    | GGCTTTTCGCTCCATGCTC       |          |                 |
| cNRXN1       | Fwd    | CCACTCTGATCATGGACCCGGG    | 392 bp   | NM_001198975.1  |
|              | Rev    | CGCCAGACCTTCACATAGT       |          |                 |
| cNRXN3       | Fwd    | GCCTGGCTCTCTCCGTGGTTC     | 394 bp   | NM_001271923.3  |
|              | Rev    | ACCCCACAAAAAGTGGCGT       |          |                 |
| cNLG1        | Fwd    | TTCCAGTGTGTCCCTAGGAG      | 170 bp   | NM_001081502.1  |
|              | Rev    | CATCACAGGCTTACTGCCC       |          |                 |
| cGAP43       | Fwd    | AGAGGCTTAAACAAAGCAGCG     | 178 bp   | NM_001305054.1  |
|              | Rev    | TGCTGGGGCACTTTCTAGTAG     |          |                 |
| C18S         | Fwd    | CTCCCTTTCTGAGTCCGTTGGT    | 100 bp   | M59389          |
|              | Rev    | TTACGACAGATGCTGCTG        |          |                 |

3.3. Reoxygenation (OGD/R) Induces Neurite Outgrowth and the Expression of Synaptogenic Markers. Figure 3(a) shows the morphological analysis of β-III-tubulin-IR hippocampal neurons with an epifluorescence microscope, to determine the effect of each treatment condition on the number of neurites, length, and branching. In comparison with the control Nx group (14.11 ± 0.8, Figures 3(a), 3(a)iv, and 3(b)), the number of neurites was significantly decreased in the OGD group to around one half (7.84 ± 0.45, p < 0.05, Figures 3(a)ii, 3(a)iii, and 3(b)), whereas the average length of the longest neurites was markedly reduced, up to 60% (300.5 ± 17.95 μm vs. 121 ± 5.2 μm, respectively; p < 0.0001, Figures 3(a)ii, 3(a)iii, and 3(c)). Interestingly, reoxygenation of the hippocampal cultures induced a partial recovery of these parameters, in comparison to the OGD group, although did not reach those in the Nx group. Thus, the number of neurites was significantly increased (11.22 ± 0.8, p < 0.001, Figures 3(a)ii, 3(a)iii, and 3(b)), and the average length was also augmented (240.9 ± 11.43 μm, p < 0.0001, Figures 3(a)ii, 3(a)iii, and 3(c)) in the OGD/R group.

The expression of several specific pre and postsynaptic markers in response to the different treatments was also studied by qPCR. It was found that the expression of NRXN1 and NRXN3 mRNAs was significantly increased (1.7-fold, p < 0.001, Figure 3(d); 1.3-fold, p < 0.05, Figure 3(e); respectively) under OGD conditions in comparison to the Nx group, but the NRXN3 expression returned to similar control levels after the OGD/R stage. On the other hand, the expression of NRXN3, NLG1, and GAP43 mRNAs was no different from the normoxic controls when the

| Size     | Accession number |
|----------|-----------------|
| 167 bp   | NM_001031616    |
| 170 bp   | NM_001004384    |
| 248 bp   | NM_001109762    |
| 153 bp   | NM_205237.3     |
| 180 bp   | NM_001001293.1  |
| 392 bp   | NM_001198975.1  |
| 394 bp   | NM_001271923.3  |
| 170 bp   | NM_001081502.1  |
| 178 bp   | NM_001305054.1  |
| 100 bp   | M59389          |
cultures were exposed to OGD injury but were significantly increased after OGD/R (1.7-fold, \( p < 0.001 \), Figure 3(e); 1.3-fold, \( p < 0.05 \), Figure 3(f); and 1.8-fold, \( p < 0.001 \), Figure 3(g); respectively).

3.4. Effects of OGD Injury and Reoxygenation (OGD/R) upon mRNA Expression of Local Neurotrophins and Growth Factors. The expression of several endogenous neurotrophins and growth factors in response to the different treatments was analyzed by qPCR. Results showed that, in comparison to the Nx controls, the exposure of hippocampal cultures to OGD injury significantly increased the mRNA expression of BDNF (3.8-fold, \( p < 0.0001 \), Figure 4(a)), IGF-1 (4.1-fold, \( p < 0.0001 \), Figure 4(b)), and BMP4 (1.6-fold, \( p < 0.001 \), Figure 4(d)). Interestingly, reoxygenation of the cultures restored the expression of these markers to similar levels as in Nx controls (Figures 4(a), 4(b), and 4(d)). On the other hand, as shown in Figure 4(c), the expression of NT-3 mRNA was significantly increased in both OGD (1.3-fold, \( p < 0.001 \)) and OGD/R (1.4-fold, \( p < 0.0001 \)) groups, respectively, in comparison to the Nx control group. Furthermore, the expression of GHR mRNA was strongly upregulated (2.9-fold, \( p < 0.001 \)) only in the OGD/R group, in comparison to the Nx and OGD groups (Figure 4(e)).

3.5. Neuroprotective Effects of GH in Hippocampal Cell Cultures Exposed to OGD and Reoxygenation (OGD/R). Figure 5(a) shows the protocol designed to determine the protective effect of GH treatment when coadministered simultaneously during OGD conditions for 24 h or during reoxygenation (OGD/R) conditions for additional 24 h, upon cell survival (MTT assay), cell number (DAPI+ nuclei), and proliferation (PCNA mRNA expression). As described before, in comparison to Nx conditions (100 ± 3.7%), OGD-injury conditions provoked a marked reduction of cell survival (down to 69.0 ± 4.87%, \( p < 0.001 \)); however, the administration of GH (1, 10, or 100 nM) induced a dose-dependent response that partially improved cell viability (77.62 ± 3.05%, 89.5 ± 1.48%, and 79.01 ± 2.34%, respectively). Interestingly, with the 10 nM GH dose, there was no statistical difference between the Nx group and the OGD + GH group (Figure 5(b)). On the other hand, Figure 5(c) shows that the cell viability was significantly reduced to 73.3 ± 3% under OGD/R in comparison to Nx group, and the GH treatment stimulated the recuperation of cell survival only at the 10 nM dose (91.61 ± 4.3%, \( p < 0.01 \)). Therefore, this was the dose selected to use in the rest of the experiments.

As shown in Figure 5(d), the administration of 10nM GH to hippocampal cultures stimulated an increase in the

![Figure 1](image1.png)

**Figure 1**: Characterization of hippocampal primary cell cultures and effects of OGD injury. (a) Typical morphology of healthy hippocampal primary cell cultures from chick embryos under normoxic conditions. (i) At day 3, neurons were small with round cell bodies and short neurites. (ii) At day 5, neurons showed longer neurites forming extensive neural networks. (iii) Merged immunofluorescence images from cultured neurons showing cell bodies stained with DAPI (blue) and neurites with β-III-tubulin (red). Scale bar: 50 μm. (b) Time course of cell survival during OGD incubation. Cell survival was evaluated by the MTT assay. (c) Representative image from hippocampal cell cultures exposed to either normoxic condition or OGD for 24 h. Scale bar: 10 μm. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to the control (\( * p < 0.05; ** p < 0.01 \)) as assessed by one-way ANOVA and Tukey as posthoc test.
Figure 2: Continued.
cell number, on either incubation condition, as compared with the corresponding controls. Figure 5(e) shows the quantitation of DAPI+ cells in each experimental condition; as mentioned before, in comparison to the Nx group, OGD injury provoked a reduction of 23.7% in the number of cells (248.9 ± 10 vs. 189.4 ± 7 cells/field, respectively), but reoxygenation (OGD/R group) significantly reversed this effect (267.2 ± 7 cells/field), stimulating a 41.1% increase in the number of DAPI+ cells in comparison to the OGD condition. The addition of 10 nM GH significantly augmented the number of cells in all the cultures compared with the untreated controls: 30.9% in the normoxic group (248.9 ± 10 vs. 325.8 ± 8 cells/field, respectively) and 78.9% in the OGD group (189.4 ± 4 vs. 338.8 ± 15 cells/field, p < 0.0001) and 28.3% in the OGD/R group (267.2 ± 7 vs. 342.9 ± 14 cells/field, p < 0.0001), respectively. Remarkably, the strongest neuroprotective effect of GH was observed in the OGD injured group (Figure 5(e)).

Figure 5(f) shows the effects of 10 nM GH treatment upon the PCNA mRNA expression in each of the experimental conditions; under normoxic environment, there was no significant differences between the GH-treated group and its nontreated control (1.43-fold, p = 0.27, Figure 5(f)i); however, the PCNA expression was appreciably increased when GH was added under OGD conditions (1.73-fold, p < 0.01, Figure 5(f)ii). In contrast, a significant reduction in the PCNA mRNA expression in the OGD/R+GH group (0.59-fold, p < 0.01, Figure 5(f)iii) was observed.

3.6. GH Reduces Apoptosis and Increases Doublecortin-IR in Hippocampal Cultures Exposed to OGD and Reoxygenation (OGD/R). Figure 6(a) shows that exposure of cells to OGD injury provoked a very significant increase (224.1 ± 4.3%, p < 0.0001) in apoptotic death, as determined by caspase-3 activity, in comparison to the Nx group (100 ± 2.5%), while reoxygenation conditions (OGD/R) mostly reversed this deleterious effect (114.2 ± 1.9%). Also, treatment of OGD injured cells with 10 nM GH effectively decreased caspase-3 activity, returning its levels to those observed in normoxic conditions (100.7 ± 5.8%).

Immunofluorescence analysis in Figure 6(b) shows the effects of the different experimental conditions upon the number of DAPI+ nuclei and the presence of DCX-IR cells. As expected, cultures exposed to OGD harm suffered a drastic reduction of DCX-IR neurons (Figure 6(b)i); however, reoxygenation conditions (OGD/R) provoked a recovery of the cultures (Figure 6(b)ii). Interestingly, GH treatment to the OGD group also annulled the noxious effect and significantly increased the number of DAPI+ and DCX-IR cells (Figure 6(b)iii). On the other hand, addition of GH under normoxic or OGD/R conditions did not show any evident changes, as compared with their respective controls.

The effects of GH during OGD and OGD/R on DCX-IR were confirmed by Western blot analysis (Figures 6(c) and 6(d)). Results showed that, in comparison to normoxic conditions (100%), OGD injury significantly reduced DCX-IR (down to 72.51 ± 25.6%, p < 0.05), while reoxygenation induced a drastic increase (up to 252.8 ± 41.6%, p < 0.05). On the other hand, administration of GH increased DCX-IR in all conditions, but it was particularly high when added to Nx condition (220 ± 48.66%, p < 0.05) and OGD injured cells (375 ± 127.9%, p < 0.05).

3.7. GH Protects and Induces Neurite Outgrowth in Cultures Exposed to OGD and Reoxygenation (OGD/R). Figure 7(a) shows the morphometric analysis performed in β-III-tubulin-IR cells present in the hippocampal cultures exposed to the different experimental conditions and treatments. It was clear that OGD injury provoked a drastic reduction in the number of immunoreactive cells and the number and length of neuronal projections (Figures 7(a)ii and 7(a)iii). These harmful effects in the OGD group were reversed by either exposing the cells to reoxygenation (Figure 7(a)ix) or by treating them with GH (Figure 7(a)x). Figure 7(b) shows

**Figure 2:** Effects of OGD and reoxygenation (OGD/R) in hippocampal cell cultures. (a) Time course schematic representation of OGD and reoxygenation (OGD/R) experimental conditions. (b) Representative immunofluorescence images showing effects of incubation conditions upon cultured hippocampal cells exposed to (i) normoxia, (ii) OGD, or (iii) OGD/R. Cell nuclei were stained with DAPI (blue) and neurons with anti-DCX (green) and anti-β-III-tubulin (red), and the images were merged. Scale bar: 50 μm. (c) Cell survival was evaluated by the MTT assay in each experimental group. (d) Quantification of cell nuclei stained with DAPI from each experimental group. (e) The expression of PCNA mRNA was analyzed by RT-qPCR. Relative mRNA expression values were corrected by the comparative threshold cycle (Ct) method and employing the formula 2^-ΔΔCt. Ribosomal 18S RNA was used as housekeeping gene. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (**p < 0.001; ****p < 0.0001), and number sign (#) shows differences between experimental groups (###p < 0.001; ####p < 0.0001) as assessed by one-way ANOVA and Tukey as posthoc test.
the corresponding quantitative analysis in each condition; in comparison to the Nx group (14.11 ± 0.8), the number of neurites was significantly reduced to almost half in the OGD group (7.84 ± 0.45, p < 0.01), whereas reoxygenation induced a partial recovery (11.22 ± 0.8) in the OGD/R group, increasing the number of neurites (43.1%) in relation to the injured group, although did not reach the Nx levels.

On the other hand, GH treatment provoked increases in...
the number of neurites in all three conditions in comparison with their respective untreated controls: Nx, 30.3%; OGD, 87.8%; and OGD/R, 19.7%, respectively. The most striking effect, by far, was observed in the OGD + GH group, where GH treatment practically reestablished the levels obtained in the Nx control (14.77 ± 0.8 vs. 11.11 ± 0.8, respectively) and almost doubled those in the injured group control (267 ± 14.6 vs. 121.7 ± 5.2 μm, p < 0.001, respectively), as well as in the OGD/R + GH group in relation to its control (295.9 ± 15.22 vs. 240.9 ± 11.42 μm, p < 0.05, respectively). The branch-order analysis revealed significant increases in the length of dendrites of the first and second order (p < 0.05; ##p < 0.001; ###p < 0.0001) as assessed by one-way ANOVA and Tukey as post hoc test. An unpaired Student’s t-test was used to compare OGD versus OGD/R (d), and the at sign (@) indicates a significant difference (@p < 0.05).

3.8. GH Promotes Synaptogenic Marker Expression in Response to OGD and Reoxygenation (OGD/R).

Figure 4: Effect of OGD and reoxygenation (OGD/R) upon BDNF, IGF-1, NT-3, BMP4, and GHR mRNA expression. Panels show the relative expression of (a) BDNF, (b) IGF-1, (c) NT-3, (d) BMP4, and (e) GHR mRNAs, determined by RT-qPCR. Relative mRNA expression values were corrected by the comparative threshold cycle (Ct) method and employing the formula 2\(^{-\Delta\Delta\text{Ct}}\). Ribosomal 18S RNA was used as housekeeping gene. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (*p < 0.05; ***p < 0.001; ****p < 0.0001), and number sign (#) shows differences between experimental groups (#p < 0.05; ##p < 0.01; ###p < 0.001) as assessed by one-way ANOVA and Tukey as post hoc test. An unpaired Student’s t-test was used to compare OGD versus OGD/R (d), and the at sign (@) indicates a significant difference (@p < 0.05).
Figure 5: Neuroprotective effects of growth hormone (GH) in hippocampal cell cultures exposed to OGD and reoxygenation (OGD/R) conditions. (a) Treatments and time course schematic representation of OGD and reoxygenation (OGD/R) protocols in the experimental groups. Cell survival was evaluated by the MTT assay in primary cultures treated with different doses (1, 10, 100 nM) of GH and exposed to (b) OGD and (c) OGD/R incubation conditions. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (**p < 0.01; ***p < 0.001), and number sign (#) shows differences between experimental groups (###, p < 0.001) as assessed by one-way ANOVA and Tukey as posthoc test. An unpaired Student’s t-test was used to compare control versus 10 nM GH (c), and the at sign (@) indicates a significant difference (@@p < 0.01). (d) Representative immunofluorescence images from each experimental group: (i) normoxia, (ii) OGD, (iii) OGD/R, (iv) normoxia + GH, (v) OGD + GH, and (vi) OGD/R + GH. Cell nuclei were stained with DAPI. Scale bar: 50 μm. (e) Quantification of the number of cells stained with DAPI in each experimental group. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (*p < 0.05), and number sign (#) shows differences between experimental groups (#p < 0.05; ####p < 0.0001) as assessed by two-way ANOVA and Tukey as posthoc test. (f) Expression of PCNA mRNA, as determined by RT-qPCR in each experimental group: (i) normoxia, (ii) OGD, and (iii) OGD/R. Relative mRNA expression values were corrected by the comparative threshold cycle (Ct) method and employing the formula $2^{-\Delta\Delta Ct}$. Ribosomal 18S RNA was used as housekeeping gene. Bars represent mean ± SEM. The at sign (@) indicates a significant difference in comparison to control (@p < 0.05) as assessed by unpaired Student’s t-test.
Figure 6: Effect of growth hormone (GH) upon apoptosis and doublecortin-immunoreactivity (DCX-IR) in hippocampal cultures exposed to OGD and reoxygenation (OGD/R) conditions. (a) Caspase-3 activity as determined with a colorimetric assay. Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (*p < 0.05; ***p < 0.0001), and number sign (#) shows differences between experimental groups (###p < 0.0001) as assessed by one-way ANOVA and Tukey as posthoc test. (b) Representative immunofluorescence merged images from each experimental group: (i) normoxia, (ii) OGD, (iii) OGD/R, (iv) normoxia + GH, (v) OGD + GH, and (vi) OGD/R + GH. Cell nuclei were stained with DAPI (blue) and neurons with anti-DCX (green). Scale bar: 50 μm. (c) Representative Western blots for DCX-IR. (d) Densitometric analysis of immunoblots for DCX-IR (corrected and normalized with GAPDH immunoreactivity). Bars represent mean ± SEM. Asterisks (*) indicate significant differences in comparison to control (*p < 0.05), and number sign (#) shows differences between experimental groups (#p < 0.05) as assessed by two-way ANOVA and Tukey as posthoc test. An unpaired Student’s t-test was used to compare control versus GH in Nx condition (d), and the at sign (@) indicates a significant difference (@p < 0.05).
Figure 7: Continued.
This work aimed to study the neuroprotective role of GH in cultured embryonic chicken hippocampal neurons exposed to both oxygen-glucose deprivation (OGD) and reoxygenation (OGD/R) injuries. We demonstrated that reoxygenation of OGD injured hippocampal neurons activate endogenous mechanisms of neuroprotection and neuroplasticity that promote cell survival, neurite outgrowth, and synaptogenesis. We also demonstrated that neurotrophic factors such as BDNF, NT-3, IGF-1, and BMP4 are increased after an acute OGD damage. Interestingly, we observed that the GHR mRNA expression (Figure 9(e)) was significantly upregulated in Nx + GH (2.7-fold, p < 0.002) and OGD + GH (1.3-fold, p < 0.002) groups, in relation to their respective untreated controls.

4. Discussion

The synaptogenic effect of GH on hippocampal cell cultures was analyzed by determining the expression of several markers by qPCR (Figure 8). It was found that NRX1 (Figure 8(a)) was significantly increased when GH was administered to the cultures under the three experimental conditions: Nx + GH (1.4-fold, p < 0.0001), OGD + GH (1.4-fold, p < 0.0006), and OGD/R + GH (3.2-fold, p < 0.03), compared with their respective untreated control groups. Similarly, the NRX3 mRNA expression (Figure 8(b)) was significantly increased in Nx + GH (1.5-fold, p < 0.0001), OGD + GH (1.6-fold, p < 0.0001), and OGD/R + GH (2.7-fold, p < 0.0001) groups, in relation to their controls. On the other hand, NLG1 (Figure 8(c)) and GAP-43 (Figure 8(d)) were significantly upregulated in the Nx + GH (1.5-fold, p < 0.001 and 1.5-fold, p < 0.0003) and the OGD + GH (1.6-fold, p < 0.0001 and 1.5-fold, p < 0.02, respectively) groups, but not in the OGD/R + GH group, compared to the untreated controls.

3.9. GH Effects upon the Expression of BDNF, IGF-1, NT-3, and GHR mRNAs in Cultures Exposed to OGD and Reoxygenation (OGD/R). BDNF mRNA expression (Figure 9(a)) was significantly increased in Nx + GH (2.6-fold, p < 0.05) and OGD + GH (1.3-fold, p < 0.005) groups, but strongly reduced (down to 0.3-fold, p < 0.005) in the OGD/R + GH group, whereas the IGF-1 expression (Figure 9(b)) was appreciably increased (1.6-fold, p < 0.001) only in the Nx + GH group, in relation to their corresponding controls. On the other hand, the NT-3 mRNA expression (Figure 9(c)) was significantly increased in Nx + GH (2.3-fold, p < 0.003) and strongly reduced (down to 0.4-fold, p < 0.0005) in the OGD/R + GH group and showed no significant effect in the OGD + GH group. In turn, the BMP4 mRNA expression (Figure 9(d)) was substantially increased only in Nx + GH (1.5-fold, p < 0.05) and OGD/R + GH (5.9-fold, p < 0.01) groups. Lastly, the GHR mRNA expression (Figure 9(e)) was significantly upregulated in Nx + GH (2.7-fold, p < 0.002) and OGD + GH (1.3-fold, p < 0.002) groups, in relation to their respective untreated controls.

This work aimed to study the neuroprotective role of GH in cultured embryonic chicken hippocampal neurons exposed to both oxygen-glucose deprivation (OGD) and reoxygenation (OGD/R) injuries. We demonstrated that reoxygenation of OGD injured hippocampal neurons activate endogenous mechanisms of neuroprotection and neuroplasticity that promote cell survival, neurite outgrowth, and synaptogenesis. We also demonstrated that neurotrophic factors such as BDNF, NT-3, IGF-1, and BMP4 are increased after an acute OGD damage. Interestingly, we observed that the GHR expression was upregulated during the reoxygenation stage. Furthermore, we found that treatment with GH enhances these neurorestorative processes by attenuating OGD-provoked neuronal apoptosis. Interestingly, GH treatment induced an increase on neurite outgrowth which positively correlated with an increase of the GAP43 expression and likely promoted synapse formation in primary hippocampal cultures after OGD injury, probably through a synergistic effect between GH and local neurotrophic factors.

In this work, we employed chicken embryonic primary hippocampal cell cultures. The rationale behind was that...
embryonic tissue is easier to dissociate, the risk of shearing damage to axons and dendrites is lower due to fewer adhesion contacts, isolation of a higher proportion of unharmed neurons is simpler, and the content of glial cells is smaller than in the adult brain tissue [40, 41]. Also, the prolonged survival and integrity of primary neuronal cultures from embryonic hippocampus are much easier to attain in comparison to mature hippocampal cultures, which present more difficulties [41]. These primary cultures are composed of several cell types, including hippocampal progenitor cells,
Neurotrophic factors

(i) Normoxia

(ii) OGD

(iii) OGD/R

Neurotrophic factors

(i) Normoxia

(ii) OGD

(iii) OGD/R

(B) IGF-1 mRNA/18S (fold)

(i) Normoxia

(ii) OGD

(iii) OGD/R

(C) NT-3 mRNA/18S (fold)

(i) Normoxia

(ii) OGD

(iii) OGD/R

(D) BMP4 mRNA/18S (fold)

(i) Normoxia

(ii) OGD

(iii) OGD/R

Figure 9: Continued.
mature neurons, and other nonneuronal cells such as oligodendrocytes and glia [40, 42, 43]. In our case, we cultured the embryonic primary neurons in serum-free Nb-B27 medium, which has been reported to improve neuronal survival and reduce growth of nonneuronal cells [40, 41, 43]. In our case, we cultured embryonic primary neurons in serum-free Nb-B27 medium, which has been reported to improve neuronal survival and reduce growth of nonneuronal cells [40, 41, 43]. In effect, we found that, after 5 days in culture, over 80% of total cells were neurons expressing β-III-tubulin-IR and DCX-IR markers and, in a lower proportion, some glial cells expressing GFAP-immunoreactivity.

Cerebral ischemia is characterized by oxygen and glucose deprivation, commonly associated with a vascular obstruction in the brain blood circulation. When the blockage is removed, the tissue is reperfused, and oxygen and nutrients are restored, in some cases, enhancing tissue damage [44, 45]. In order to mimic a stroke injury, we used oxygen and glucose deprivation (OGD) and reoxygenation (OGD/R) of embryonic chick primary hippocampal cultures, as an in vitro cerebral ischemia-reperfusion model. Our results showed that the application of OGD during 24 h caused a severe damage in the neuronal cultures, by reducing cell survival to 64% in comparison with the normoxic conditions (98.2%) at the same incubation time. These data are consistent with findings reported in rat organotypic hippocampal slice cultures [46] and in ovo experiments where hypoxia for 24 h produced severe structural alterations in the hippocampus of chick embryos [47]. In contrast, we did not observe significant damage in OGD incubation during 1 or 6 h, as previously reported in murine primary cortical cultures [48], probably because hippocampal neurons are more resistant to hypoxic-ischemic insults [49]. Interestingly, when OGD injured neurons were reoxygenated for another 24 h, cell survival was significantly increased. These results contradict previous in vitro studies in mouse cortical and cerebellar cells reporting that reperfusion induced apoptosis and excitotoxic necrotic cell death by an overproduction of reactive oxygen species (ROS) [50, 51]. Recently, it was reported that reoxygenation decreased cell viability and increased necrosis in chicken cerebellar cell cultures [52]. Conversely, our results showed that hippocampal cell number was increased after the OGD/R phase. Furthermore, we observed that these conditions also increased the PCNA mRNA expression (3.3-fold), suggesting that reoxygenation activates proliferative responses that could influence the cell density. These findings are in accord with previous reports indicating that an ischemic insult promoted the proliferation of neural stem cells in the dentate gyrus of the rat hippocampus [17].

It has been described that after cerebral ischemia injury, neurite interconnections shrink and degenerate, thus losing the capacity to integrate neural networks [3]; although, it was shown that dendritic alteration in injured neurons can be reversed under certain conditions [53–56]. Previous studies performed in the visual cortex of the rat showed that, after damage, neurons may retain the capacity to survive, and injury-induced dendritic degeneration can be prevented, possibly through a mechanism known as axotomy, which consists of disconnecting the neurons that project to the site of injury, that activates a cascade of molecular and cellular events leading to the death of only the disconnected cells [55]. These results suggested that neurites are able to regenerate in functional neuronal networks and with partial recovery after neural harm [57]. Our results clearly showed that OGD significantly reduced the number and length of neurites in the hippocampal cultures. However, after the OGD/R phase, the morphometric parameters of those neurons were partially reestablished, probably due to the plastic capacity of neural cells to adapt to hypoxic conditions [58–60]. It is known that if the dendritic morphology is altered, then the synaptic capacity is also modified [61]; therefore, we evaluated the effects of OGD and OGD/R incubation conditions upon synaptic protection and regeneration.

Neurexins (NXRNs) and neuroligin-1 (NLG1) are synaptic cell-adhesion proteins that interact between pre and postsynaptic neurons, both are well-established markers of synaptic function in the hippocampus [62], and recently have been associated with neuroregeneration in damaged neuroretina [12]. Here, we found that NRXN3 and NLG1 mRNA expression showed no changes after OGD injury, as compared with the Nx conditions; however, after the
OGD/R stage, their expression was significantly increased. Furthermore, GAP43, a synaptogenic marker associated to neurite outgrowth [63], was also increased after OGD/R. These data are consistent with our morphometric findings, in which we observed a significant increase in the number and length of neurites after the OGD/R phase. Taken together, our results suggest that OGD injured neurons activate endogenous mechanisms of neuroprotection and neuroplasticity that promote neurite outgrowth and functional synopsis formation during the OGD/R stage.

The mechanisms behind the brain capacity to promote neuroplasticity in response to neural lesions are still largely unknown. It has been reported that the expression and release of endogenous neurotrophic factors are altered by various experimental models of CNS injuries, including ischemic models [4, 25, 29]. After ischemic harm, the expression of growth factors such as BDNF, NT-3, and IGF-1 was increased [18–20]. These growth factors have been implicated in brain development, and their expression was increased after neural injury [64]. In this work, we found that the expression of BDNF, NT-3, and IGF-1 mRNAs was increased after OGD, and this clearly correlated with recovery effects observed after incubation in OGD/R conditions. It is known that BMP4 can act as a neurotrophic factor involved in the modulation of neurogenesis and plasticity in the hippocampus [65]. Also, a moderate although significant increase in the expression of BMP4 mRNA was observed in subcortical white matter following cerebral ischemia [66]. We noticed that the BMP4 mRNA expression was significantly increased after OGD injury, but returned to normoxic control levels after exposing the hippocampal cultures to OGD/R conditions. Our results insinuate that endogenous mechanisms of neuroprotection and neuroplasticity in response to an OGD injury could at least be partially mediated by the expression of neurotrophic factors (e.g., BDNF, NT-3, IGF-1, and BMP4).

It is known that GHR is expressed in several brain areas, including the hippocampus [67–69]. Moreover, it was described that the expression of GHR was strongly upregulated during recovery from focal hypoxic-ischemic brain injury, in the penumbra and infarcted regions of the cortex [22, 70]. In accordance with those results, here, we found a significant increase in the expression of GHR mRNA when the harmed cells were exposed to the reoxygenation phase, indicating that OGD injured neurons might be highly responsive to GHR which, in turn, could induce restorative effects upon these neurons.

Also, GH can induce neuroprotection after cerebral stroke in humans [4–6] and in other animal models [4, 29, 71, 72]. After ischemic stroke, GH mRNA expression and GH content were increased in the rat hippocampus by chronic hypoxia [4], and treatment with exogenous GH-effectively reduced hippocampal cell loss [22, 71, 73]. In accordance with those reports, our results demonstrated that GH was capable to significantly increase cell viability in OGD injured neurons. We found a dose-dependent response to GH administration upon cell viability, which exhibited a typical bell-shaped curve of GHR activation [74], and having an optimal effect at the 10 nM dose. The prosurvival actions of GH in response to neural lesions are well established; for example, GH treatment increased cell viability in primary chicken cerebellar cultures exposed to hypoxic-ischemic incubation conditions [24], as well as in avian and reptilian neuroretinal cells exposed to excitotoxic damage with kainate or glutamate [75–78], indicating a conserved neuroprotective action within the vertebrate CNS. Interestingly, the addition of GH during the OGD/R did not have a significant effect on cell viability; a possible explanation is that the apoptotic cell death process occurs during the first hours of OGD exposition, in accordance with previous reports [79], suggesting that neuroprotective actions of GH are required during the initial phase of injury.

GH is a potent mitogenic factor capable to exert a proliferative effect over striatal cells under normal conditions [8]. This mitogenic activity seemed to be important to protect hippocampal neurons against prolonged sleep loss [80]. Here, we observed that GH treatment during OGD and OGD/R conditions increased the number of cells in the cultures. This increase was apparently due to a proliferative effect of GH, since its presence promoted PCNA mRNA expression, thus indicating that growth hormone could have the potential to exert a direct mitogenic effect upon hippocampal cells in response to damage.

Doublecortin is a neural progenitor cell marker expressed in immature neurons during development and adult neurogenesis; it is associated with neuronal migration, axon growth, dendritic remodeling, and synapse maturation [81, 82]. We noticed the wide DCX expression in our embryonic hippocampal cultures, indicating that newly formed neurons were present. Our results showed that OGD significantly reduced the number of DCX+ cells while exposure to OGD/R conditions reversed those effects, probably due to the endogenous mechanisms of restoration mentioned previously. Recently, new actions for the DCX family have been associated to cell survival and regeneration [83]; therefore, it is possible that GH neuroprotective effects include DCX involvement, since we found that GH treatment during OGD injury significantly increased DCX-IR, to reach similar levels as in the normoxic controls. Likewise, GH addition during OGD/R maintained the effect observed during OGD harm. These results support the notion that GH may exert a neurotrophic action to promote neuron survival, in accordance with analogous reports in embryonic striatal neural precursor cells [8]. The mechanism by which GH could exert its neuroprotective effects could be associated with an antiapoptotic action reported previously for this hormone in the neural retina [7, 75, 78, 84], cerebellum [24, 52], and hippocampus [71]. Accordingly, we observed that caspase-3 activity was strongly increased during OGD injury, and then significantly reduced after the cells were exposed to OGD/R conditions. Interestingly, the addition of GH during ODG conditions provoked a striking reduction of caspase-3 activity, suggesting that prosurvival actions of GH in hippocampal neurons are exerted through an antiapoptotic mechanism.

Besides increasing apoptotic and necrotic cell death, the deleterious effects provoked by hypoxic-ischemic injury also included important morphological and synaptic changes,
such as a reduction of neurite number and length. Beneficial effects of GH treatment upon structural and synaptic plasticity have been reported, either by increasing the dendritic length and number of dendritic spines in the cortex and hippocampus of the rat [10, 11], by regulating the expression of α-amino-3-hydroxyl-5-methyl-4-isoxazol-propionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors, or by increasing the expression of postsynaptic density 95 protein [85]. Here, we demonstrated that GH treatment improved structural and synaptic plasticity in the injured hippocampal cell cultures. Thus, GH addition increased the number and length of primary neurites in OGD conditions, while under the OGD/R phase, it only augmented the length of neurites of the second order of branching. These results suggest that GH has two important actions in this respect: during OGD, GH protects existing neurites, and during OGD/R stage, it promotes their growth, enhancing the endogenous neurorestorative mechanisms noticed in the OGD/R conditions. To explore the molecular mechanisms by which GH promoted neurite outgrowth when added during OGD injury, we also analyzed the expression of GAP-43 mRNA. As mentioned earlier, GAP-43 plays a role in axonal growth and branching [86]. Indeed, another report showed that the GAP-43 expression was upregulated in retinal ganglion cells after ischemia-induced damage [87]. As shown above, we observed that GAP-43 may play an important role in neurite regeneration, forming new neural circuits during OGD/R condition. Here, we presented, for the first time, that GH upregulated the GAP-43 mRNA expression in neurons exposed to OGD conditions, suggesting that GH facilitated...
neurite outgrowth in cultured hippocampal injured neurons via this pathway.

The administration of GH induced a significant increase in the mRNA expression of NRXNs and NLG1, implying beneficial effects upon synaptic plasticity in the OGD injured neurons. Interestingly, a stronger upregulation of these synaptic markers was observed when GH was added during OGD/R. Considering that NRXNs and NLG1 are important for the generation of long-term potentiation (LTP), which is positively regulated by GH [88] and is associated with synaptic plasticity and cognitive processes, our results may contribute to explain the improvements in cognitive functions that have been reported in animal models [27, 28, 85], GH-deficient patients [89], and brain-injured patients who receive GH replacement therapy [6, 13–15].

Initially, we hypothesized that the partial recovery observed in several parameters when the OGD injured hippocampal neurons were exposed to reoxygenation and normal glucose conditions (OGD/R) could be explained by the activation of an endogenous mechanism of neuroprotection and neuroplasticity mediated by neurotrophic factors such as BDNF, NT-3, IGF-1, and BMP4, whose expression was upregulated in response to hypoxia-ischemia injury. Remarkably, the addition of GH to the harmed cultures upgraded this endogenous recovery response to levels similar to those found under normoxic conditions. Thus, it is possible that GH acts together with the local neurotrophic factors to repair the damage caused by OGD conditions.

To analyze this further, we evaluated the effect of GH treatment on BDNF, NT-3, IGF-1, and BMP4 mRNA expression under Nx, OGD, and OGD/R experimental conditions. We found that GH promoted a significant increase of these four neurotrophic factors under normoxic conditions, indicating that GH modulates them under physiological conditions. However, under OGD injury, only the BDNF expression was significantly upregulated by GH treatment. This is consistent with results where GH administration stimulated the synthesis of BDNF in animals with traumatic brain injury and improved cognitive functions [29]. Since BDNF promotes neuronal survival, neurite outgrowth, and synaptic function and plasticity [90], actions that are similar to those produced by GH in the present study, it is possible that the GH-stimulated BDNF expression during OGD conditions plays an important role in hippocampal neuron recovery. In contrast, this result was not mirrored under OGD/R conditions, since GH treatment provoked a marked reduction in the expression of BDNF and NT-3 mRNAs, suggesting their involvement in the recovery observed during the reoxygenation phase is under a complex regulation; these findings deserve further research. On the other hand, GH administration induced a significant upregulation of the BMP4 expression under both Nx and OGD/R conditions, but not when added during OGD injury. BMP4 has been associated with differentiation of neuronal stem cells (NSCs) and neuroprotection [91, 92]. Here, we provided evidence that this factor was induced by GH in the hippocampal neurons, an effect similar to that reported in the retinal tissue [12]. Considering that BMP4 promotes neurite outgrowth [93], it is possible that this neurotrophic factor acts together with GH to potentiate the restorative effect that was observed in the number and length of neurites in this study.

5. Conclusions

As shown in Figure 10, this work provides evidence that, in response to OGD injury, reoxygenated hippocampal neurons are capable to activate endogenous mechanisms of neuroprotection and neuroplasticity that involve the local expression of several neurotrophins, and this in turn contributes to reverse some of the negative effects provoked by hypoxia-ischemia. This endogenous response is clearly enhanced by GH treatment, which protects from OGD injury and stimulates a significant increase in cell survival, exerts a clear antiapoptotic action, induces neurite outgrowth and branching, and promotes synaptogenesis, probably through a synergistic combination between its own effect and that of the local neurotrophic factors. This complex regulation deserves further investigation.

Data Availability

The data used to support the findings of this study are included within the article. If further information is needed, it can be available from the corresponding author upon request.

Ethical Approval

This study was conducted according to the guidelines established in “The guide for care and use of laboratory animals”, U.S. National Research Council, as well as in the Mexican official regulation (NOM-062-ZOO-1999), and was approved by the bioethical committee of the Instituto de Neurobiología, UNAM (protocol 038, 10/19/2010, ratified on 09/12/2017).

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Conceptualization was contributed by J.D.O.-H. and C.A. Methodology was contributed by J.D.O.-H., J.E.B.-M., M.C., M.L., and C.G.M.-M.. Supervision was contributed by C.A., J.D.O.-H., C.G.M.-M., and M.L. Writing—original draft was contributed by J.D.O.-H., C.G.M.-M., and C.A. Writing—review and editing was contributed by C.A., J.D.O.-H., and M.L. Resources and funding were contributed by C.A., M.L., and C.G.M.-M. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors thank Pilgrim’s Pride, Querétaro, México, who donated fertilized broiler eggs used during this research. We also thank Dr. José Ávila-Mendoza for critically reading the manuscript, as well as Gerardo Courtois (Lab assistant),
Nydia Hernández-Ríos, at the INB-UNAM Microscopy Unit, Adriana González-Gallardo, at the INB-UNAM Proteogenomic Unit, and Ramón Martínez-Olvera, at the INB-UNAM Computing Unit, for technical support. This work was supported by grants IN208419, IN227020, and IN209621, from Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica de la Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (PIAPIIT-DGAPA-UNAM, Mexico City, Mexico) and UNAM grant 1130-202-002 to C.A., as well as by grants 285004 and CF 2019-214971 from Consejo Nacional de Ciencia y Tecnología (CONACYT, Mexico City, Mexico) and UNAM grant 1130-202-002 to C.A., as well as by grants 285004 and CF 2019-214971 from Consejo Nacional de Ciencia y Tecnología (CONACYT, Mexico City, Mexico). Postdoctoral fellowship to J.D.O.-H (# 261533) and M.Sc. scholarship to J.E.B.-M. (# 921788) were provided by CONACYT.

Supplementary Materials

Immunofluorescence characterization of primary hippocampal cell cultures showing the relative proportion of neurons (DCX-IR) and glial cells (GFAP-IR) at different culture times. (Supplementary Materials)

References

[1] D. J. Hausenloy and D. M. Yellon, “Ischaemic conditioning and reperfusion injury,” *Nature Reviews Cardiology*, vol. 13, no. 4, pp. 193–209, 2016.

[2] A. Datta, D. Sarmah, L. Mounica et al., “Cell death pathways in ischemic stroke and targeted pharmacotherapy,” *Translational Stroke Research*, vol. 11, no. 6, pp. 1185–1202, 2020.

[3] J. Chen, A. Zacharek, X. Cui et al., “Treatment of stroke with a synthetic liver X receptor agonist, TO901317, promotes synaptic plasticity and axonal regeneration in mice,” *Journal of Cerebral Blood Flow & Metabolism*, vol. 30, no. 1, pp. 102–109, 2010.

[4] R. C. Li, S. Z. Guo, M. Raccurt et al., “Exogenous growth hormone attenuates cognitive deficits induced by intermittent hypoxia in rats,” *Neuroscience*, vol. 196, pp. 237–250, 2011.

[5] V. M. Arce, P. Devesa, and J. Devesa, “Role of growth hormone (GH) in the treatment on neural diseases: from neuroprotection to neural repair,” *Neuroscience Research*, vol. 76, no. 4, pp. 179–186, 2013.

[6] J. Devesa, B. Alonso, N. Casteliero et al., “Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study,” *Therapeutics and Clinical Risk Management*, vol. 7, pp. 199–206, 2011.

[7] S. Harvey, M. L. Baudet, and E. J. Sanders, “Growth hormone-induced neuroprotection in the neural retina during chick embryogenesis,” *Annals of the New York Academy of Sciences*, vol. 1163, no. 1, pp. 414–416, 2009.

[8] C. Regalado-Santiago, M. L. López-Meraz, J. Santiago-García, C. Fernández-Pomares, and E. Juárez-Aguilar, “Growth hormone (GH) is a survival rather than a proliferative factor for embryonic striatal neural precursor cells,” *Growth Hormone & IGF Research*, vol. 23, no. 5, pp. 179–186, 2013.

[9] N. D. Åberg, J. Lind, J. Isgaard, and K. H. Georg, “Peripheral growth hormone induces cell proliferation in the intact adult rat brain,” *Growth Hormone & IGF Research*, vol. 20, no. 3, pp. 264–269, 2010.

[10] J. D. Olivares-Hernández, F. García-García, I. Camacho-Abrego, G. Flores, and E. Juárez-Aguilar, “Intracerebroventricular administration of growth hormone induces morphological changes in pyramidal neurons of the hippocampus and prefrontal cortex in adult rats,” *Synapse*, vol. 72, no. 7, article e22030, 2018.

[11] E. Nylander, S. Zelleroth, F. Stam, F. Nyberg, A. Grönbladh, and M. Hallberg, “Growth hormone increases dendritic spine density in primary hippocampal cell cultures,” *Growth Hormone & IGF Research*, vol. 50, pp. 42–47, 2020.

[12] C. G. Martínez-Moreno, D. Epardo, J. E. Balderas-Márquez et al., “Regenerative effect of growth hormone (GH) in the retina after kainic acid excitotoxic damage,” *International Journal of Molecular Sciences*, vol. 20, no. 18, p. 4433, 2019.

[13] V. Bhagia, C. Gilkison, R. H. Fitts et al., “Effect of recombinant growth hormone replacement in a growth hormone deficient subject recovering from mild traumatic brain injury: A case report,” *Brain Injury*, vol. 24, no. 3, pp. 560–567, 2010.

[14] P. Reimunde, A. Quintana, B. Castañoñ et al., “Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury,” *Brain Injury*, vol. 25, no. 1, pp. 65–73, 2011.

[15] J. B. Wamstad, K. W. Norwood, A. D. Rogol et al., “Neuropsychological recovery and quality-of-life in children and adolescents with growth hormone deficiency following TBI: a preliminary study,” *Brain Injury*, vol. 27, no. 2, pp. 200–208, 2013.

[16] A. G. Douen, L. Dong, S. Vanance et al., “Regulation of nestin expression after cortical ablation in adult rat brain,” *Brain Research*, vol. 1008, no. 2, pp. 139–146, 2004.

[17] L. L. Zhu, L. Y. Wu, D. T. Yew, and M. Fan, “Effects of hypoxia on the proliferation and differentiation of NSCs,” *Molecular Neurobiology*, vol. 31, no. 1-3, pp. 231–242, 2005.

[18] S. K. Madathil, S. W. Carlson, J. M. Brelsfoard, P. Ye, A. J. D’Ercole, and K. E. Saatman, “Astrocyte-specific overexpression of insulin-like growth factor-1 protects hippocampal neurons and reduces behavioral deficits following traumatic brain injury in mice,” *PLoS ONE*, vol. 8, no. 6, article e67204, 2013.

[19] J. T. Neumann, J. W. Thompson, A. P. Raval, C. H. Cohan, K. B. Koronowski, and M. A. Perez-Pinzon, “Increased BDNF protein expression after ischemic or PKC epsilon preconditioning promotes electrophysiologic changes that lead to neuroprotection,” *Journal of Cerebral Blood Flow & Metabolism*, vol. 35, no. 1, pp. 121–130, 2015.

[20] J. Y. Chung, M. W. Kim, W. Im, I. K. Hwang, M. S. Bang, and M. Kim, “Expression of neurotrophin-3 and trkC following focal cerebral ischemia in adult rat brain with treadmill exercise,” *BioMed Research International*, vol. 2017, Article ID 9248542, 6 pages, 2017.

[21] J. Houlton, N. Abumaria, S. Hinkley, and A. N. Clarkson, “Therapeutic potential of neurotrophins for repair after brain injury: A helping hand from biomaterials,” *Frontiers in Neuroscience*, vol. 13, p. 790, 2019.

[22] A. Scheepens, E. S. Sirimanne, B. H. Breier, R. G. Clark, P. D. Gluckman, and C. E. Williams, “Growth hormone as a neurotrophic factor during recovery from CNS injury,” *Neuroscience*, vol. 104, no. 3, pp. 677–687, 2001.

[23] L. J. Christophidis, T. Gorba, M. Gustavsson et al., “Growth hormone receptor immunoreactivity is increased in the
subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis,” *Growth Hormone & IGF Research*, vol. 19, no. 6, pp. 497–506, 2009.

[24] C. Alba-Betancourt, J. L. Luna-Acosta, C. E. Ramirez-Martínez et al., “Neuro-protective effects of growth hormone (GH) after hypoxia–ischemia injury in embryonic chicken cerebellum,” *General and Comparative Endocrinology*, vol. 183, pp. 17–31, 2013.

[25] S. Jung, G. Boie, H. G. Doerr, and R. Trollmann, “Oxygen-sensitive regulation and neuroprotective effects of growth hormone-dependent growth factors during early postnatal development,” *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 312, no. 4, pp. R539–R548, 2017.

[26] L. K. Ong, W. Z. Chow, C. TeBay et al., “Growth hormone improves cognitive function after experimental stroke,” *Stroke*, vol. 49, no. 5, pp. 1257–1266, 2018.

[27] S. Sanchez-Bezanilla, N. D. Åberg, P. Crock et al., “Growth hormone promotes motor function after experimental stroke and enhances recovery-promoting mechanisms within the peri-infarct area,” *International Journal of Molecular Sciences*, vol. 21, no. 2, p. 606, 2020.

[28] S. Sanchez-Bezanilla, N. D. Åberg, P. Crock et al., “Growth hormone treatment promotes remote hippocampal plasticity after experimental cortical stroke,” *International Journal of Molecular Sciences*, vol. 21, no. 12, p. 4563, 2020.

[29] H. Zhang, M. Han, X. Zhang, X. Sun, and F. Ling, “The effect and mechanism of growth hormone replacement on cognitive function in rats with traumatic brain injury,” *PLoS One*, vol. 9, no. 9, article e108518, 2014.

[30] W. M. High, M. Briones-Galang, J. A. Clark et al., “Effect of growth hormone replacement therapy on cognition after traumatic brain injury,” *Journal of Neurotrauma*, vol. 27, no. 9, pp. 1565–1575, 2010.

[31] J. Devesa, G. Díaz-Getino, P. Rey et al., “Brain recovery after a plane crash: treatment with growth hormone (GH) and neurorehabilitation: a case report,” *International Journal of Molecular Sciences*, vol. 16, no. 12, pp. 30470–30482, 2015.

[32] K. A. Mossberg, W. J. Durham, D. J. Zgaljardic et al., “Functional changes after recombinant human growth hormone replacement in patients with chronic traumatic brain injury and abnormal growth hormone secretion,” *Journal of Neurotrauma*, vol. 34, no. 4, pp. 845–852, 2017.

[33] M. Gasperi and A. E. Castellano, “Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases,” *Journal of Endocrinological Investigation*, vol. 33, no. 8, pp. 587–591, 2014.

[34] C. G. Martínez-Moreno, D. Calderón-Vallejo, S. Harvey, C. Arámburu, and J. L. Quintanar, “Growth hormone (GH) and gonadotropin-releasing hormone (GnRH) in the central nervous system: A potential neurological combinatorial therapy?,” *International Journal of Molecular Sciences*, vol. 19, no. 2, p. 375, 2018.

[35] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method,” *Methods*, vol. 25, no. 4, pp. 402–408, 2001.

[36] J. Vandesompele, K. De Preter, F. Pattyn et al., “Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes,” *Genome Biology*, vol. 3, no. 7, article research0034.1, 2002.

[37] A. Bas, G. Forsberg, S. Hammarström, and M. L. Hammarström, “Utility of the housekeeping genes 18S rRNA, β-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes,” *Scandinavian Journal of Immunology*, vol. 59, no. 6, pp. 566–573, 2004.

[38] J. L. Luna-Acosta, C. Alba-Betancourt, C. G. Martínez-Moreno et al., “Direct antiapoptotic effects of growth hormone are mediated by PI3K/Akt pathway in the chicken bursa of Fabricius,” *General and Comparative Endocrinology*, vol. 224, pp. 148–159, 2015.

[39] J. Schindelin, I. Arganda-Carreras, E. Frise et al., “Fiji: an open-source platform for biological-image analysis,” *Nature Methods*, vol. 9, no. 7, pp. 676–682, 2012.

[40] G. J. Brewer, “Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus,” *Journal of Neuroscience Research*, vol. 42, no. 5, pp. 674–683, 1995.

[41] G. J. Brewer, “Isolation and culture of adult rat hippocampal neurons,” *Journal of Neuroscience Methods*, vol. 71, no. 2, pp. 143–155, 1997.

[42] B. Ray, J. A. Bailey, S. Sarkar, and D. K. Lahiri, “Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: Differential expression of neuronal and glial protein markers,” *Journal of Neuroscience Methods*, vol. 184, no. 2, pp. 294–302, 2009.

[43] C. N. Svendsen, J. W. Fawcett, C. Bentlage, and S. B. Dunnett, “Increased survival of rat EGF-generated CNS precursor cells using B27 supplemented medium,” *Experimental Brain Research*, vol. 102, no. 3, pp. 407–414, 1995.

[44] J. Aronowski, R. Strong, and J. C. Grotta, “Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats,” *Journal of Cerebral Blood Flow & Metabolism*, vol. 17, no. 10, pp. 1048–1056, 1997.

[45] V. Fellman and K. O. Raivio, “Reperfusion injury as the mechanism of brain damage after perinatal asphyxia,” *Pediatric Research*, vol. 41, no. 5, pp. 599–606, 1997.

[46] S. Cho, D. Liu, D. Fairman et al., “Spatiotemporal evidence of apoptosis-mediated ischemic injury in organotypic hippocampal slice cultures,” *Neurochemistry International*, vol. 45, no. 1, pp. 117–127, 2004.

[47] C. L. Rodricks, M. E. Gibbs, G. Jenkins, and S. L. Miller, “The effect of hypoxia at different embryonic ages on impairment of memory ability in chicks,” *International Journal of Developmental Neuroscience*, vol. 26, no. 1, pp. 113–118, 2008.

[48] E. Landucci, R. Lattanzi, E. Gerace et al., “Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro,” *Neuropharmacology*, vol. 108, pp. 39–48, 2016.

[49] A. P. Horn, D. Gerhardt, A. B. Geyer et al., “Cellular death in hippocampus in response to PI3K pathway inhibition and oxygen and glucose deprivation,” *Neurochemical Research*, vol. 30, no. 3, pp. 355–361, 2005.

[50] B. J. Gwag, D. Lobner, J. Y. Koh, M. B. Wie, and D. W. Choi, “Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro,” *Neuroscience*, vol. 68, no. 3, pp. 615–619, 1995.
and necrosis in cerebellar granule cells,” *Neuroscience Letters*, vol. 240, no. 1, pp. 21–24, 1998.

[52] R. Baltazar-Lara, J. Ávila-Mendoza, C. G. Martínez-Moreno et al., “Neuroprotective effects of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1) after hypoxic-ischemic injury in chicken cerebellar cell cultures,” *International Journal of Molecular Sciences*, vol. 22, no. 1, p. 256, 2021.

[53] J. S. Park, M. C. Bateman, and M. P. Goldberg, “Rapid alterations in dendritic morphology during sublethal hypoxia or glutamate receptor activation,” *Neurobiology of Disease*, vol. 3, no. 3, pp. 215–227, 1996.

[54] G. F. Tseng and M. E. Hu, “Axotomy induces retraction of the dendritic arbor of adult rat rubrospinal neurons,” *Cells Tissues Organs*, vol. 155, no. 3, pp. 184–193, 1996.

[55] S. Zhang, J. Boyd, K. Delaney, and T. H. Murphy, “Rapid reversible changes in dendritic spine structure in vivo gated by the degree of ischemia,” *Journal of Neuroscience*, vol. 25, no. 22, pp. 5333–5338, 2005.

[56] M. L. Hendrickson, C. Ling, and R. E. Kalil, “Degeneration of axotomized projection neurons in the rat dlGN: temporal progression of events and their mitigation by a single administration of FGF2,” *PLoS ONE*, vol. 7, no. 11, article e46918, 2012.

[57] N. Y. Harel and S. M. Strittmatter, “Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury?,” *Nature Reviews Neuroscience*, vol. 7, no. 8, pp. 603–616, 2006.

[58] G. W. Lu, X. Y. Cui, and B. M. Zhao, “Alteration of oxygen consumption and energy metabolism during repetitive exposure of mice to hypoxia,” *Neurochemical Research*, vol. 24, no. 5, pp. 625–628, 1999.

[59] J. Ara and S. De Montpellier, “Hypoxic-preconditioning enhances the regenerative capacity of neural stem/progenitors in subventricular zone of newborn piglet brain,” *Stem Cell Research*, vol. 11, no. 2, pp. 669–686, 2013.

[60] M. Y. Xu, Y. F. Wang, P. J. Wei, Y. Q. Gao, and W. T. Zhang, “Hypoxic preconditioning improves long-term functional outcomes after neonatal hypoxia-ischemic injury by restoring white matter integrity and brain development,” *CNS Neuroscience & Therapeutics*, vol. 25, no. 6, pp. 734–747, 2019.

[61] H. Chen, W. Lin, Y. Zhang et al., “IL-10 promotes neurite outgrowth and synapse formation in cultured cortical neurons after the oxygen-glucose deprivation via JAK1/STAT3 pathway,” *Scientific Reports*, vol. 6, no. 1, 2016.

[62] T. C. Südhof, “Neuroligin and neurexins link synaptic function to cognitive disease,” *Nature*, vol. 455, no. 7215, pp. 903–911, 2008.

[63] L. I. Benowitz and A. Routtenberg, “GAP-43: an intrinsic determinant of neuronal development and plasticity,” *Trends in Neurosciences*, vol. 20, no. 2, pp. 84–91, 1997.

[64] A. Larpthaveesarp, D. M. Ferriero, and F. F. Gonzalez, “Growth factors for the treatment of ischemic brain injury (growth factor treatment),” *Brain Sciences*, vol. 5, no. 2, pp. 165–177, 2015.

[65] H. Xu, W. Huang, Y. Wang et al., “The function of BMP4 during neurogenesis in the adult hippocampus in Alzheimer’s disease,” *Aging Research Reviews*, vol. 12, no. 1, pp. 157–164, 2013.

[66] J. Chang, R. W. Dettman, and M. L. Dizon, “Bone morphogenetic protein signaling: a promising target for white matter protection in perinatal brain injury,” *Neural Regeneration Research*, vol. 13, no. 7, p. 1183, 2018.

[67] P. E. Lobie, J. García-Aragón, D. T. Lincoln, R. Barnard, J. N. Wilcox, and M. J. Waters, “Localization and ontogeny of growth hormone receptor gene expression in the central nervous system,” *Developmental Brain Research*, vol. 74, no. 2, pp. 225–233, 1993.

[68] F. Nyberg and P. Burman, “Growth hormone and its receptors in the central nervous system -location and functional significance,” *Hormone Research*, vol. 45, no. 1-2, pp. 18–22, 1996.

[69] M. Le Grevès, P. Steensland, P. Le Grevès, and F. Nyberg, “Growth hormone induces age-dependent alteration in the expression of hippocampal growth hormone receptor and N-methyl-D-aspartate receptor subunits gene transcripts in male rats,” *Proceedings of the National Academy of Sciences*, vol. 99, no. 10, pp. 7119–7123, 2002.

[70] A. Scheepens, E. Sirimanne, E. Beilharz et al., “Alterations in the neural growth hormone axis following hypoxic-ischemic brain injury,” *Molecular Brain Research*, vol. 68, no. 1-2, pp. 88–100, 1999.

[71] D. H. Shin, E. Lee, J. W. Kim et al., “Protective effect of growth hormone on neuronal apoptosis after hypoxia-ischemia in the neonatal rat brain,” *Neuroscience Letters*, vol. 354, no. 1, pp. 64–68, 2004.

[72] T. R. Han, M. H. Chun, D. H. Jang, K. S. Kim, K. H. Lim, and H. J. Cho, “Neuroprotective effects of growth hormone against hypoxic-ischemic brain injury in neonatal rats: 1H magnetic resonance spectroscopic study,” *Journal of Korean Medical Science*, vol. 22, no. 1, pp. 122–126, 2007.

[73] K. Gustafson, H. Hagberg, B. A. Bengtsson, C. Brantings, and J. Isgaard, “Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats,” *Pediatric Research*, vol. 45, no. 3, pp. 318–323, 1999.

[74] G. Fuh, B. C. Cunningham, R. Fukunaga, S. Nagata, D. V. Goeddel, and J. A. Wells, “Rational design of potent antagonists to the human growth hormone receptor,” *Science*, vol. 256, no. 5064, pp. 1677–1680, 1992.

[75] J. Ávila-Mendoza, J. Mora, M. Carranza, M. Luna, and C. Arámburu, “Growth hormone reverses excitotoxic damage induced by kainic acid in the gerbil hippocampus,” *General and Comparative Endocrinology*, vol. 234, pp. 57–67, 2016.

[76] T. Fleming, C. G. Martínez-Moreno, M. Carranza, M. Luna, S. Harvey, and C. Arámburu, “Growth hormone promotes synaptogenesis and protects neuroretinal dendrites against kainic acid (KA) induced damage,” *General and Comparative Endocrinology*, vol. 265, pp. 111–120, 2018.

[77] C. G. Martínez-Moreno, J. Ávila-Mendoza, Y. Wu et al., “Neuroprotection by GH against excitotoxic-induced cell death in retinal ganglion cells,” *General and Comparative Endocrinology*, vol. 234, pp. 68–80, 2016.

[78] C. G. Martínez-Moreno, T. Fleming, M. Carranza et al., “Growth hormone protects against kainate excitotoxicity and induces BDNF and NT3 expression in chicken neuroretinal cells,” *Experimental Eye Research*, vol. 166, pp. 1–12, 2018.

[79] A. Kalda and A. Zharkovsky, “Metabotropic glutamate receptor agonists protect from oxygen-glucose deprivation and colchicine-induced apoptosis in primary cultures of cerebellar granule cells,” *Neuroscience*, vol. 92, no. 1, pp. 7–14, 1999.

[80] F. García-García, K. Alberto, E. Juárez-Aguilar et al., “Growth hormone improves hippocampal adult cell survival and counteracts the inhibitory effect of prolonged sleep deprivation on...
cell proliferation,” *Brain Research Bulletin*, vol. 84, no. 3, pp. 252–257, 2011.

[81] J. G. Gleeson, P. T. Lin, L. A. Flanagan, and C. A. Walsh, “Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons,” *Neuron*, vol. 23, no. 2, pp. 257–271, 1999.

[82] B. T. Schaar, K. Kinoshita, and S. K. McConnell, “Doublecortin micro-tubule affinity is regulated by a balance of kinase and phosphatase activity at the leading edge of migrating neurons,” *Neuron*, vol. 41, no. 2, pp. 203–213, 2004.

[83] H. Nawabi, S. Belin, R. Cartoni et al., “Doublecortin-like kinases promote neuronal survival and induce growth cone reformation via distinct mechanisms,” *Neuron*, vol. 88, no. 4, pp. 704–719, 2015.

[84] E. J. Sanders, W. Y. Lin, E. Parker, and S. Harvey, “Growth hormone promotes the survival of retinal cells in vivo,” *General and Comparative Endocrinology*, vol. 172, no. 1, pp. 140–150, 2011.

[85] M. Le Grevès, Q. Zhou, M. Berg et al., “Growth hormone replacement in hypophysectomized rats affects spatial performance and hippocampal levels of NMDA receptor subunit and PSD-95 gene transcript levels,” *Experimental Brain Research*, vol. 173, no. 2, pp. 267–273, 2006.

[86] C. J. Donnelly, M. Park, M. Spillane et al., “Axonally synthesized β-actin and GAP-43 proteins support distinct modes of axonal growth,” *Journal of Neuroscience*, vol. 33, no. 8, pp. 3311–3322, 2013.

[87] F. Dijk, A. A. Bergen, and W. Kamphuis, “GAP-43 expression is upregulated in retinal ganglion cells after ischemia/reperfusion-induced damage,” *Experimental Eye Research*, vol. 84, no. 5, pp. 858–867, 2007.

[88] D. P. Molina, O. J. Ariwodola, C. Linville et al., “Growth hormone modulates hippocampal excitatory synaptic transmission and plasticity in old rats,” *Neurobiology of Aging*, vol. 33, no. 9, pp. 1938–1949, 2012.

[89] M. Elbornsson, A. Horvath, G. Götherström, B. A. Bengtsson, G. Johannsson, and J. Svensson, “Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency,” *European Journal of Endocrinology*, vol. 176, no. 2, pp. 99–109, 2017.

[90] W. J. Tyler and L. Pozzo-Miller, “Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurons,” *The Journal of Physiology*, vol. 553, no. 2, pp. 497–509, 2003.

[91] B. S. Moon, J. Y. Yoon, M. Y. Kim, S. H. Lee, T. Choi, and K. Y. Choi, “Bone morphogenetic protein 4 stimulates neuronal differentiation of neuronal stem cells through the ERK pathway,” *Experimental and Molecular Medicine*, vol. 41, no. 2, pp. 116–125, 2009.

[92] A. Fischer, M. Schmidt, G. Omar, and T. A. Reh, “BMP4 and CNTF are neuroprotective and suppress damage-induced proliferation of Müller glia in the retina,” *Molecular and Cellular Neuroscience*, vol. 27, no. 4, pp. 531–542, 2004.

[93] A. Thompson, M. Berry, A. Logan, and Z. Ahmed, “Activation of the BMP4/Smad1 pathway promotes retinal ganglion cell survival and axon regeneration,” *Investigative Ophthalmology & Visual Science*, vol. 60, no. 5, pp. 1748–1759, 2019.